Relay Therapeutics Inc (RLAY) Unusual Options Activity Today

Checking RLAY unusual options activity helps you spot when traders are making outsized bets on Relay Therapeutics Inc before the broader market catches on. Relay Therapeutics Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor RLAY unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching RLAY unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking RLAY unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and RLAY unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors.

It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Catalysts rarely arrive without a footprint, and RLAY unusual options activity is often where that footprint shows up first. Our scanner tracks Relay Therapeutics Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at RLAY unusual options volume on the call side or chasing put sweeps, Relay Therapeutics Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.